Assenagon Asset Management S.A. Purchases 72,826 Shares of AngioDynamics, Inc. $ANGO

Key Points

• Assenagon Asset Management S.A. increased its holdings in AngioDynamics, Inc. by 30.4%, acquiring 72,826 shares to reach a total of 312,707 shares, valued at approximately $3.1 million.
• AngioDynamics reported a quarterly earnings per share (EPS) of ($0.03), outperforming analysts' estimates, with revenues of $80.16 million, reflecting a 13% year-over-year increase.
• Analysts' reviews of AngioDynamics stock have been positive, with multiple upgrades and a consensus "Buy" rating, alongside price targets reaching as high as $24.00.

Assenagon Asset Management S.A. boosted its position in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 30.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 312,707 shares of the medical instruments supplier's stock after acquiring an additional 72,826 shares during the period. Assenagon Asset Management S.A. owned 0.77% of AngioDynamics worth $3,102,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. ProShare Advisors LLC bought a new stake in shares of AngioDynamics in the fourth quarter worth about $100,000. Cerity Partners LLC lifted its holdings in AngioDynamics by 22.0% in the 1st quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier's stock worth $121,000 after buying an additional 2,333 shares during the period. GAMMA Investing LLC grew its position in shares of AngioDynamics by 1,281.4% in the 1st quarter. GAMMA Investing LLC now owns 13,897 shares of the medical instruments supplier's stock worth $130,000 after buying an additional 12,891 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new position in shares of AngioDynamics during the first quarter valued at approximately $139,000. Finally, Fox Run Management L.L.C. bought a new position in shares of AngioDynamics during the first quarter valued at approximately $145,000. 89.43% of the stock is owned by institutional investors.

AngioDynamics Stock Performance

ANGO stock opened at $10.72 on Thursday. The firm has a market capitalization of $435.55 million, a price-to-earnings ratio of -12.92 and a beta of 0.64. The firm has a 50 day moving average price of $9.65 and a 200-day moving average price of $9.66. AngioDynamics, Inc. has a 52-week low of $5.83 and a 52-week high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its quarterly earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.09. The firm had revenue of $80.16 million for the quarter, compared to analysts' expectations of $74.26 million. AngioDynamics had a negative net margin of 11.62% and a negative return on equity of 3.20%. The business's revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.06) earnings per share. AngioDynamics has set its FY 2026 guidance at -0.350--0.250 EPS. As a group, sell-side analysts forecast that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on ANGO shares. Wall Street Zen upgraded shares of AngioDynamics from a "hold" rating to a "buy" rating in a report on Saturday, August 16th. Canaccord Genuity Group boosted their price target on shares of AngioDynamics from $15.00 to $17.00 and gave the company a "buy" rating in a research report on Wednesday, July 16th. Lake Street Capital started coverage on shares of AngioDynamics in a research note on Wednesday, July 16th. They issued a "buy" rating and a $24.00 price target for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $16.00 price objective on shares of AngioDynamics in a research report on Wednesday, July 16th. Three analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $19.00.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.